Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
Recruiting
Observational Study
Hepatocellular Carcinoma (HCC)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 12 (estimated)
- Sponsor
- Palo Alto Veterans Institute for Research · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to determine if baseline liquid biopsy assays (CTC and cf-DNA) as well as single circulating tumor cell-DNA (sCTC DNA) dynamics in the early post-treatment period can predict subsequent treatment response to Y-90 radioembolization in patients with hepatocellular carcinoma (HCC).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age \> or = 18 years
2. HCC confirmed on imaging, BCLC stage 0, A, B, or C
3. Transarterial Y90 radioembolization approved by multidisciplinary tumor board -
Exclusion Criteria:
1. Not eligible for Y90 procedure
2. Prior surgery or ablation on indicated tumors
3. Patient un…
Contacts